Key terms

About BLTE

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BLTE news

Yesterday 7:27am ET Belite Bio, Inc Announces New Securities Agreement by TipRanks Mar 22 9:25am ET Buy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market Potential by TipRanks Mar 22 8:27am ET Belite Bio Advances Retinal Disease Treatment by TipRanks Mar 22 8:02am ET Belite Bio announces PMDA submission of Tinlarebant for trial in Japan by TipRanks Mar 21 2:16am ET Buy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong Financials by TipRanks Mar 18 7:10am ET Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO) by TipRanks Mar 14 7:40am ET Analysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX) by TipRanks Mar 13 6:20am ET Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA) by TipRanks Mar 12 5:15am ET Belite Bio reports Q4 EPS (27c), consensus (30c) by TipRanks Mar 11 9:33pm ET Belite Bio reports Q4 EPS (27c), consensus (30c) by TipRanks Feb 27 10:25am ET Belite Bio participates in a conference call with Benchmark by TipRanks Feb 27 4:55am ET Belite Bio participates in a conference call with Benchmark by TipRanks Feb 21 4:04pm ET Belite Bio participates in a conference call with Benchmark by TipRanks

No recent press releases are available for BLTE

BLTE Financials

1-year income & revenue

Key terms

BLTE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BLTE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Student demonstrators occupy the pro-Palestinian "Gaza Solidarity Encampment" on the West Lawn of Columbia University on April 24, 2024 in New York City.
Michael M. Santiago/Getty Images
What the pro-Palestinian protesters on college campuses actually want
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stagflation fears just hit Wall Street. Now for the next crucial report on prices
Meta headquarters pictured on February 02, 2023 in Menlo Park, California.
Justin Sullivan/Getty Images
Meta’s stock plunges 15% on ‘aggressive’ AI spending plans
GettyImages-1159438448 copy.jpg
Lyndon Stratford/iStockphoto/Getty Images
Americans are falling behind on their payments